This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
RENE Overzicht aandelen
Researches, develops, and commercializes cell-based therapies in the United Kingdom.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
ReNeuron Group plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | UK£0.034 |
| 52 Week Hoogtepunt | UK£0.11 |
| 52 Week Laag | UK£0.033 |
| Bèta | 0.69 |
| 11 maand verandering | 0% |
| 3 maanden verandering | -2.17% |
| 1 Jaar Verandering | -58.59% |
| 33 jaar verandering | -97.71% |
| 5 jaar verandering | -98.75% |
| Verandering sinds IPO | -99.87% |
Recent nieuws en updates
Recent updates
We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully
Jul 15
We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate
Jan 22Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth
Oct 12Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?
Jun 04Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?
Jan 12
Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)
Nov 20Rendement voor aandeelhouders
| RENE | GB Biotechs | GB Markt | |
|---|---|---|---|
| 7D | 0% | 3.0% | 0.1% |
| 1Y | -58.6% | -15.6% | 9.7% |
Rendement versus industrie: RENE underperformed the UK Biotechs industry which returned -26.8% over the past year.
Rendement versus markt: RENE underperformed the UK Market which returned 3% over the past year.
Prijsvolatiliteit
| RENE volatility | |
|---|---|
| RENE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.5% |
Stabiele aandelenkoers: RENE has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: Insufficient data to determine RENE's volatility change over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 26 | n/a | www.reneuron.com |
ReNeuron Group plc Samenvatting
| RENE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | UK£1.93m |
| Inkomsten(TTM) | -UK£5.07m |
| Inkomsten(TTM) | UK£249.00k |
7.7x
P/S-verhouding-0.4x
Koers/WinstverhoudingIs RENE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RENE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | UK£249.00k |
| Kosten van inkomsten | UK£3.65m |
| Brutowinst | -UK£3.40m |
| Overige uitgaven | UK£1.67m |
| Inkomsten | -UK£5.07m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
May 30, 2024
| Winst per aandeel (EPS) | -0.089 |
| Brutomarge | -1,367.47% |
| Nettowinstmarge | -2,037.35% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde RENE op de lange termijn?
Bekijk historische prestaties en vergelijking